Most researchers searching for CJC-1295 in Recea rapidly learn that local retail options are essentially nonexistent. The practical advantage of this online-only market is that serious vendors differentiate entirely through their analytical documentation, giving researchers access to better quality signals than any local market ever offers. Separating quality CJC-1295 from the rest of the market comes down to three things: an HPLC chromatogram showing ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. Use this guide to verify vendor quality systematically — the quality evaluation approach outlined here work regardless of your location.
Understanding CJC-1295 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Recea researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Quality CJC-1295 sourcing begins with a straightforward question: does this vendor publish batch-specific COAs proactively? Vendors who do are demonstrating research-grade standards. The HPLC purity trace is the most important document in the COA: it should show a clear dominant peak representing CJC-1295, with negligible secondary peaks representing impurities — purity should be 98% or higher. Red flags in CJC-1295 vendor evaluation: prices far under typical market pricing, no information about manufacturing source, no community presence, and COAs that omit endotoxin testing. Price is an ineffective primary criterion for CJC-1295 quality — research-grade synthesis and testing has real costs that do not compress without quality compromise, so unusually low prices consistently indicate quality reductions.
Order CJC-1295 — ships to Recea
COA-verified · International tracking · Research grade
CJC-1295 is available for research use only and is not approved for human therapeutic use by the FDA or equivalent regulatory bodies — all information here is provided for educational purposes. Proper handling of CJC-1295 requires strict sterile technique during reconstitution — alcohol-swabbed septum, fresh needles, clean working environment — and consistent cold chain handling. Endotoxin testing in the CJC-1295 COA is not optional — gram-negative bacterial endotoxins can trigger severe inflammatory responses at very low concentrations, and no cost saving makes omitting this acceptable. PubMed and related preprint servers are the primary literature resources for CJC-1295 research; prioritise peer-reviewed studies with characterised source material over case reports or anecdotal evidence.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
